Source: Annual Congress 2007 - Asthma subphenotypes
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
On behalf of the BIOAIR study group, I. Delin, M. Kumlin, S. E. Dahlén (Stockholm, Sweden). Increased urinary LTE₄ in severe asthma and COPD: interim report from the BIOAIR study. Eur Respir J 2007; 30: Suppl. 51, 3172

Member's Comments

No comment yet.

Related content which might interest you: Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007 Phenotypic markers of asthma and COPD at the tissue level Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Why is it important to consider (sub)phenotypes of asthma and COPD? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005 Clinical value of C-reactive protein in severe acute exacerbations of COPD Source: Annual Congress 2005 - COPD - acute exacerbations Year: 2005 CC10 and TIMP1 levels in induced sputum of smokers who developed chronic airflow impairment Source: Annual Congress 2005 - Experimental approaches to the study of chronic cough and cigarette smoking Year: 2005 Lung function and sputum neutrophil changes in an experimental model of virus-induced COPD exacerbations Source: Annual Congress 2005 - COPD: role of infection Year: 2005 Mechanisms of exacerbation of respiratory symptoms in patients with COPD Source: Research Seminar 2006 - Complexity of patients with multiple chronic diseases Year: 2006 Impact of bronchial airflow limitation and recent respiratory tract infection on the circulating level of C-reactive protein in an elderly population Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD Source: Eur Respir J 2009; 34: 95-102 Year: 2009 Pharmacological characterisation of indacaterol (QAB149), a novel once-daily inhaled β2-agonist, on small airways in human and rat lung slices Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006 Desmosin as a marker for tissue injury in COPD Source: Annual Congress 2007 - α1-Antitrypsin deficiency: molecular and clinical news Year: 2007 Relationships between C-reactive protein and disability in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2005 - Systemic effects of COPD Year: 2005 The serum level of surfactantproteind in patients with chronic obstructive pulmonary disease, depending on the nutrtional status Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 COPD: problems in diagnosis and measurement Source: Eur Respir J 2003; 21: 4S-12S Year: 2003 Where current pharmacological therapies fall short in COPD: symptom control is not enough Source: Eur Respir Rev 2007; 16: 98-104 Year: 2007 Eosinophilic airway inflammation as a complication of COPD, and the usefulness of ICS on these cases Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Misdiagnosed COPD: systematic review and meta-analysis Source: Annual Congress 2007 - Delivering respiratory care: the challenges for primary care Year: 2007 Medication use in COPD: systematic review and meta-analysis Source: Annual Congress 2007 - Treatment and care of COPD Year: 2007